Gyre Therapeutics Inc (GYRE) Inventory Turnover Ratio, from third quarter 2026 to third quarter 2025, current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 
Gyre Therapeutics Inc   (NASDAQ: GYRE)
 

Gyre Therapeutics Inc Inventory Turnover Ratio (COS)

Cost of Sales Formula, Quarterly Results, Trends, Rankings, Statistics

Due to inventory build up in the third quarter 2026, Gyre Therapeutics Inc 's inventory turnover ratio sequentially decreased to 0.63 in the third quarter 2026, unsurprisingly, as the Gyre Therapeutics Inc markets continue to deteriorate, and GYRE's faces growing challenges to bring down its inventories. Gyre Therapeutics Inc 's average inventory processing period in the Sep 30 2026 quarter, has increased to 579 days, from 562 days, in the Jun 30 2026 quarter.

Within Healthcare sector 342 other companies have achieved higher inventory turnover ratio. While in terms of ranking among all other companies, the company has moved form 1590 in the second quarter 2026, to 1878.

GYRE Inventory Turnover Ratio using Sales Formula
What is Inventory Turnover Ratio?
What is Gyre Therapeutics Inc Market Share?

What is Inventory Turnover Ratio?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GYRE Inventory Turnover Ratio (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Inventory Growth 38.01 % 28.97 % 44.1 % 60.5 % 38.8 %
Y / Y Cost of Sales Growth 19.59 % 91.92 % 37.25 % 48.09 % 69.94 %
Inventory Turnover Ratio (TTM) 0.63 0.65 0.59 0.61 0.61
GYRE's Total Ranking # 1878 # 1590 # 1434 # 1189 #
Average inventory processing period 578 560 623 603 601
Seq. Inventory Growth 6.92 % 0.67 % 11.61 % 14.87 % -0.08 %
Seq. Cost of Sales Growth -11.86 % 80.03 % -29.6 % 7.06 % 41.44 %




Inventory Turnover Ratio Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 105
Healthcare Sector # 343
Overall Market # 1878

Inventory Turnover Ratio Statistics
High Average Low
0.75 0.63 0.57
(Sep 30 2024)   (Jun 30 2025)



GYRE Company Profile >> Back to GYRE Efficiency Comparisons >> Compare GYRE Inventory Turnover Ratio to its Competitors

Financial Statements
Gyre Therapeutics Inc 's Inventories $ 12 Millions Visit GYRE's Balance sheet
Gyre Therapeutics Inc 's Cost of Revenues TTM $ 7 Millions Visit GYRE's Income Statement
What are GYRE's Sales? Visit GYRE's Sales by Segment

Other Inventory Turnover Ratios
Gyre Therapeutics Inc 's Inventory to Sales Ratio
U.S. Durable Goods Inventory to Shipment Ratio By Product
Major Pharmaceutical Preparations Industry Inventory Turnover Trends and Statistics
Healthcare Sector Inventory Turnover Statistics
Inventory Turnover Trends for overall market
GYRE's Inventory Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Inventory Turnover
Lowest Ranking Inventory Turnover
Inventory Turnover for GYRE's Competitors
Inventory Turnover Ratio for GYRE's Suppliers
Inventory Turnover Ratio for GYRE's Customers

You may also want to know
GYRE's Sales Growth Rates GYRE's Pe Price to earnings ratio GYRE's Receivables Turnover Ratio GYRE's Stock Quote
GYRE's Net Income Growth Rates GYRE's Ps Price to Sales ratio GYRE's Sales per Employee GYRE's Asset Turnover Ratio
GYRE's Net Margin GYRE's Pb Price to Book ratio GYRE's Financial Strength Ratios GYRE's Dividend Payout Ratio



Companies with similar Inventory Turnover Ratio for the quarter ending Sep 30 2026, within Healthcare Sector Inventory Turnover Ratio Cost of revenues at quarter ending Sep 30 2026 Inventories at quarter ending Sep 30 2026
Sanuwave Health Inc   1.54 $ 9.845  Millions$ 6  Millions
Humacyte Inc   1.53 $ 13.780  Millions$ 9  Millions
Waters Corporation  1.51 $ 1,797.864  Millions$ 1,192  Millions
Axogen inc   1.49 $ 68.923  Millions$ 46  Millions
Cormedix Inc   1.47 $ 52.080  Millions$ 36  Millions
Aurinia Pharmaceuticals Inc   1.29 $ 30.165  Millions$ 23  Millions
Hyperfine Inc   1.28 $ 8.502  Millions$ 7  Millions
Pulmonx Corporation  1.28 $ 20.450  Millions$ 16  Millions
Alphatec Holdings Inc   1.27 $ 241.341  Millions$ 189  Millions
Si bone inc   1.25 $ 46.999  Millions$ 38  Millions
Bridgebio Pharma Inc   1.24 $ 53.542  Millions$ 43  Millions
Biogen Inc   1.23 $ 2,681.800  Millions$ 2,181  Millions
Lensar Inc   1.22 $ 28.813  Millions$ 24  Millions
Kiniksa Pharmaceuticals International Plc  1.21 $ 93.072  Millions$ 77  Millions
Mannkind Corporation  1.16 $ 51.332  Millions$ 44  Millions
Rhythm Pharmaceuticals Inc   1.14 $ 33.056  Millions$ 29  Millions
Penumbra Inc  1.13 $ 499.548  Millions$ 443  Millions
Teleflex Incorporated  1.12 $ 427.166  Millions$ 380  Millions
Acadia Pharmaceuticals Inc   1.12 $ 114.422  Millions$ 102  Millions
Corcept Therapeutics Inc  1.11 $ 14.097  Millions$ 13  Millions
Bio Green Med Solution Inc   1.10 $ 1.180  Millions$ 1  Millions
Alkermes Plc   1.10 $ 300.119  Millions$ 273  Millions
Neurocrine Biosciences Inc   1.07 $ 81.200  Millions$ 76  Millions
Emergent Biosolutions Inc   1.07 $ 334.800  Millions$ 314  Millions
Seer Inc   1.03 $ 7.698  Millions$ 7  Millions
Neuropace Inc   1.03 $ 17.563  Millions$ 17  Millions
Vertex Pharmaceuticals Inc  1.00 $ 1,874.100  Millions$ 1,866  Millions
Beone Medicines Ltd   0.99 $ 701.426  Millions$ 708  Millions
Amarin Corp Plcuk  0.92 $ 104.502  Millions$ 113  Millions
Eli Lilly And Company  0.89 $ 14,149.700  Millions$ 15,815  Millions

Date modified: 2026-11-07T13:17:42+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.